Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9.
Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9.
复制标题
DOI:
10.1016/j.stem.2014.10.004
复制
发表时间:
2014-11-06
期刊:
影响因子:
23.9
通讯作者:
Cowan, Chad A.
中科院分区:
文献类型:
--
作者:
Mandal, Pankaj K.;Ferreira, Leonardo M. R.;Collins, Ryan;Meissner, Torsten B.;Boutwell, Christian L.;Friesen, Max;Vrbanac, Vladimir;Garrison, Brian S.;Stortchevoi, Alexei;Bryder, David;Musunuru, Kiran;Brand, Harrison;Tager, Andrew M.;Allen, Todd M.;Talkowski, Michael E.;Rossi, Derrick J.;Cowan, Chad A.
Genome editing via CRISPR/Cas9 has rapidly become the tool of choice by virtue of its efficacy and ease of use. However, CRISPR/Cas9 mediated genome editing in clinically relevant human somatic cells remains untested. Here, we report CRISPR/Cas9 targeting of two clinically relevant genes, B2M and CCR5, in primary human CD4+ T cells and CD34+ hematopoietic stem and progenitor cells (HSPCs). Use of single RNA guides led to highly efficient mutagenesis in HSPCs but not in T cells. A dual guide approach improved gene deletion efficacy in both cell types. HSPCs that had undergone genome editing with CRISPR/Cas9 retained multi-lineage potential. We examined predicted on- and off-target mutations via target capture sequencing in HSPCs and observed low levels of off-target mutagenesis at only one site. These results demonstrate that CRISPR/Cas9 can efficiently ablate genes in HSPCs with minimal off-target mutagenesis, which could have broad applicability for hematopoietic cell-based therapy.
登录
查看更多内容
影响因子:
7
作者:
Cho SW;Kim S;Kim Y;Kweon J;Kim HS;Bae S;Kim JS
通讯作者:
Kim JS
影响因子:
46.9
作者:
通讯作者:
--
影响因子:
17.3
作者:
Gaj, Thomas;Gersbach, Charles A.;Barbas, Carlos F., III
通讯作者:
Barbas, Carlos F., III
影响因子:
56.9
作者:
Jinek, Martin;Chylinski, Krzysztof;Charpentier, Emmanuelle
通讯作者:
Charpentier, Emmanuelle
影响因子:
64.5
作者:
Niu, Yuyu;Shen, Bin;Sha, Jiahao
通讯作者:
Sha, Jiahao